NCT00045422View on ClinicalTrials.gov

Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

April 30, 2002

Primary Completion Date

October 31, 2003

Study Completion Date

October 31, 2003

Conditions
Leukemia
Interventions
BIOLOGICAL

recombinant interferon alfa

DRUG

imatinib mesylate

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00045422 - Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | Biotech Hunter | Biotech Hunter